Cancer patients experience better outcomes with at-home injections, according to new Cigna Healthcare study; the site-of-care redirection program increased the accessibility and affordability of pegfilgrastim, which stimulates white blood cell growth

Sample article from our Health Care Sector

BLOOMFIELD, Connecticut , June 13, 2023 (press release) –

 A new study by Cigna Healthcare found that site-of-care redirection is associated with favorable clinical outcomes and increased access and affordability for peg¬filgrastim, an injection used to prevent infection in cancer patients. The results showed that patients experienced better outcomes when the injection was administered in a home setting rather than a nonhome setting. The study was recently published in the Journal of Clinical Pathways This link will open in a new tab. .
"This study shows that we can help improve health outcomes by providing cancer patients with treatment such as infusions in a setting where many are most comfortable – home," said Dr. Scott Josephs, chief medical officer, Cigna Healthcare. "These findings confirm that home infusion of complex and expensive specialty medications presents new opportunities to maximize access, improve effectiveness, increase affordability, and enhance convenience for patients."
The study, Pegfilgrastim Home Redirection Outcomes: Effectiveness and Timing of Administration in Primary Prophylaxis of Chemotherapy-Induced Neutropenia This link will open in a new tab. (Lavanya Raj, MBBS, MS; Pam McManus), examined the impact of Cigna's site-of-care home redirection program on pegfilgrastim effectiveness and timing of administration in preventing complications from chemotherapy among Cigna's commercial patients. Pegfilgrastim injections stimulate healthy white blood cell growth, which is critical for cancer patients who face an increased risk of infection due to cancer treatment.
The study found that the incidence of neutropenia (abnormally low count of white blood cells), fever, pneumonia, and sepsis was 32% lower in patients who underwent home redirection compared with those who did not. Similarly, the odds of same-day pegfilgrastim administration were 43% lower in patients who underwent home redirection. This retrospective, real-world claims study presents significant evidence supporting favorable clinical outcomes associated with Cigna's site-of-care home-redirection program for pegfilgrastim.
Cigna's site-of-care redirection program provides access to pegfilgrastim and other injected or infused treatments in a home setting when clinically appropriate, rather than a hospital, and where patients can have a home health nurse instruct them on self-administration. This program offers additional benefits, such as minimizing hospital visits for patients with cancer, who are at an increased risk of infection, the convenience of in-home administration, and avoidance of costs and logistics associated with traveling to another location 24 hours after chemotherapy administration. This program, which also often offers patients the option of infusions in their physician's office, emphasizes high-value care, optimizing patient outcomes, and enhancing the patient experience.
About the study
The study's sample consisted of 13,493 patients receiving chemotherapy between September 1, 2020, and August 31, 2022. Each of these patients had received pegfilgrastim or its biosimiliars for febrile neutropenia prophylaxis. These drugs were eligible for redirection under the Cigna Healthcare pro¬gram and were redirected from a high-cost setting to a qual¬ity, cost-effective clinically appropriate site of care, such as a contracted provider's office, customer's home with infusion nurses, or nonhospital-based ambulatory infusion center. Breast, colorectal, lung/ bronchus, non-Hodgkin lymphoma, pancreatic, ovarian, and uterine cancers comprised approximately 80% of patient can¬cer types.
About Cigna Healthcare 
Cigna Healthcare is a health benefits provider that advocates for better health through every stage of life. We guide our customers through the health care system, empowering them with the information and insight they need to make the best choices for improving their health and vitality. Products and services are provided exclusively by or through operating subsidiaries of The Cigna Group (NYSE:CI), including Cigna Health and Life Insurance Company, Connecticut General Life Insurance Company, Evernorth Health companies or their affiliates and Express Scripts companies or their affiliates. Such products and services include an integrated suite of health services, such as medical, dental, behavioral health, pharmacy, vision, supplemental benefits and others. Learn more at This link will open in a new tab. .
Media Contact
Meaghan MacDonald
(860) 840-1212 This link will open in a new tab.


* All content is copyrighted by Industry Intelligence, or the original respective author or source. You may not recirculate, redistrubte or publish the analysis and presentation included in the service without Industry Intelligence's prior written consent. Please review our terms of use.

See our dashboard in action - schedule an demo
Dan Rivard
Dan Rivard
- VP Market Development -

We offer built-to-order health care sector coverage for our clients. Contact us for a free consultation.

About Us

We deliver market news & information relevant to your business.

We monitor all your market drivers.

We aggregate, curate, filter and map your specific needs.

We deliver the right information to the right person at the right time.

Our Contacts

1990 S Bundy Dr. Suite #380,
Los Angeles, CA 90025

+1 (310) 553 0008

About Cookies On This Site

We collect data, including through use of cookies and similar technology ("cookies") that enchance the online experience. By clicking "I agree", you agree to our cookies, agree to bound by our Terms of Use, and acknowledge our Privacy Policy. For more information on our data practices and how to exercise your privacy rights, please see our Privacy Policy.